Best Treatment for Concurrent Hidradenitis Suppurativa and Psoriatic Arthritis
For patients with both hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), adalimumab is the single best treatment option as it is the only FDA-approved biologic with Level 1 evidence for HS and has strong evidence for PsA. 1, 2
Primary Recommendation: Adalimumab
Adalimumab should be dosed at 160 mg at week 0,80 mg at week 2, then 40 mg weekly starting at week 4 for HS 1. This dosing regimen demonstrated:
- 42-59% HiSCR response rates at 12 weeks in the PIONEER trials (versus 26-28% with placebo)
- Statistically significant improvement (p = 0.003 in PIONEER 1)
- Nearly 40% of initial non-responders achieved response by week 36 with continued treatment 1
For the PsA component, adalimumab is a well-established TNF inhibitor with strong efficacy data 2.
Alternative Options if Adalimumab Fails
Second-Line: Infliximab
If adalimumab fails or causes adverse events, infliximab 5-10 mg/kg every 4-8 weeks is the next best choice 1:
- 78% response rate (55 of 71 patients) in systematic review
- Significant improvements in DLQI, pain VAS, and PGA scores
- Expert experience suggests titration to 10 mg/kg every 4-8 weeks may be necessary for optimal HS control
- Also effective for PsA 2
Third-Line: IL-12/23 or IL-17 Inhibitors
For patients failing TNF inhibitors:
- IL-12/23 inhibitors (ustekinumab, guselkumab, tildrakizumab) are conditionally recommended for PsA 2 and emerging case reports show efficacy for concurrent HS/psoriasis 3
- IL-17 inhibitors (secukinumab, ixekizumab) are conditionally recommended for PsA 2, though data for HS is limited
Avoid: Etanercept and Anakinra
- Etanercept showed no statistically significant improvement in HS in controlled trials 1
- Anakinra should only be considered after TNF inhibitor failure 1 and has shown mixed results in case reports 4
Critical Pitfalls to Avoid
- Do not use etanercept - despite being a TNF inhibitor, it lacks efficacy for HS 1
- Weekly adalimumab dosing is essential - standard every-other-week dosing used for PsA alone is insufficient for HS 1
- Nearly half of week 12 responders lose response by week 36 - counsel patients about potential need for dose escalation or switching 1
- Consider continuing methotrexate during biologic transitions for PsA to maintain disease control 2
Adjunctive Therapies
While initiating biologics:
- Topical clindamycin 1% for mild HS lesions (though increases S. aureus resistance) 1
- Intralesional triamcinolone 10 mg/mL for individual inflamed HS nodules - provides rapid pain relief within 1 day 1
- Systemic antibiotics (rifampin + clindamycin) may be used as bridge therapy 1
Monitoring Strategy
Assess HS response using HiSCR (Hidradenitis Suppurativa Clinical Response) at 12 weeks 1. For non-responders at 12 weeks who continue adalimumab, reassess at 36 weeks as nearly 40% achieve delayed response 1. Monitor PsA activity using standard rheumatologic assessments 2.